{"id":7325,"date":"2015-04-08T15:34:04","date_gmt":"2015-04-08T15:34:04","guid":{"rendered":""},"modified":"2015-04-08T15:34:04","modified_gmt":"2015-04-08T15:34:04","slug":"ivabradino-klinikiniu-tyrimu-apzvalga","status":"publish","type":"post","link":"https:\/\/www.pasveik.lt\/lt\/naujausi-medicinos-straipsniai\/ivabradino-klinikiniu-tyrimu-apzvalga\/7325\/","title":{"rendered":"Ivabradino klinikini\u0173 tyrim\u0173 ap\u017evalga"},"content":{"rendered":"<p style=\"text-align: justify;\">Ivabradinas \u2013 i\u0161eminei \u0161irdies ligai (I\u0160L) ir \u0161irdies nepakankamumui (\u0160N) gydyti patvirtintas antianginini\u0173 ir antii\u0161emini\u0173 savybi\u0173 turintis selektyvus specifinis sinusinio mazgo I<em>f <\/em>srov\u0117s inhibitorius. Jis selektyviai suma\u017eina \u0161irdies susitraukim\u0173 da\u017en\u012f (\u0160SD) l\u0117tindamas diastolin\u0119 depoliarizacij\u0105 ir nedaro reik\u0161mingos \u012ftakos hemodinamikos rodikliams. \u0160iame ap\u017evalginiame straipsnyje apibendrinamos naujausios \u017einios apie ivabradino veiksmingum\u0105 gydant I\u0160L ir \u0160N sergan\u010dius pacientus. Turima patikim\u0173 mokslini\u0173 \u012frodym\u0173, patvirtinan\u010di\u0173 ivabradino veiksmingum\u0105 ma\u017einantkr\u016btin\u0117s anginos simptomus bei miokardo i\u0161emij\u0105. \u012evairi\u0173 klinikini\u0173 tyrim\u0173 duomenys pagrind\u017eia ivabradino efektyvum\u0105 gydant l\u0117tin\u012f \u0160N. Ivabradinas ma\u017eindamas \u0160SD, pagerina \u0160N sergan\u010di\u0173 pacient\u0173 fizinio kr\u016bvio toleravim\u0105, suma\u017eina kartotinio hospitalizavimo d\u0117l pablog\u0117jusio \u0160N ir mir\u010di\u0173 nuo jo da\u017enum\u0105. Ivabradinas \u2013 gan naujas vaistas, kur\u012f Europos vaist\u0173 agent\u016bra (EVA) 2005 metais patvirtino I\u0160L sergan\u010di\u0173 pacient\u0173,kurie netoleruoja beta adrenoreceptori\u0173 blokatori\u0173 (BAB),kr\u016btin\u0117s anginai ir miokardo i\u0161emijai gydyti. V\u0117liau ivabradino taikymo klinikin\u0117je praktikoje indikacijos i\u0161pl\u0117stos: jis patvirtintas vartoti kartu su BAB gydant I\u0160L ar \u0160N sergan\u010dius pacientus. Ivabradinas yra pirmasis klinikin\u0117je praktikoje vartojamas selektyvus specifinis sinusinio mazgo I<em>f <\/em>srov\u0117s inhibitorius. Kitaip nei BAB ir kalcio kanal\u0173 blokatoriai, ivabradinas \u0160SD ma\u017eina selektyviai ir specifi\u0161kai slopindamas mi\u0161ri\u0105 natrio ir kalio jon\u0173 srov\u0119 sinusinio mazgo l\u0105stel\u0117se. I\u0161 ties\u0173, ma\u017eindamas spontanin\u0117s diastolin\u0117s sinusinio mazgo miocit\u0173 depoliarizacijos greit\u012f ir slopindamas I<em>f <\/em>srov\u0119, ivabradinas pailgina l\u0117tos depoliarizacijos faz\u0119, tod\u0117l suma\u017e\u0117ja \u0160SD . \u0160is poveikis n\u0117ra lydimas joki\u0173 neigiam\u0173 inotropini\u0173 ar dromotropini\u0173 pasekmi\u0173. \u0160iame straipsnyje ap\u017evelgiami svarbiausi tyrimai, patvirtinantys ivabradino veiksmingum\u0105 gydant \u0160KL sergan\u010dius pacientus.<\/p>\n<p><strong>\u00a0<img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"\" alt=\"Ivabradino klinikini\u0173 tyrim\u0173 ap\u017evalga\"><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ivabradinas \u2013 i\u0161eminei \u0161irdies ligai (I\u0160L) ir \u0161irdies nepakankamumui (\u0160N) gydyti patvirtintas antianginini\u0173 ir antii\u0161emini\u0173 savybi\u0173 turintis selektyvus specifinis sinusinio mazgo If srov\u0117s inhibitorius. Jis selektyviai suma\u017eina \u0161irdies susitraukim\u0173 da\u017en\u012f (\u0160SD) l\u0117tindamas diastolin\u0119 depoliarizacij\u0105 ir nedaro reik\u0161mingos \u012ftakos hemodinamikos rodikliams. \u0160iame ap\u017evalginiame straipsnyje apibendrinamos naujausios \u017einios apie ivabradino veiksmingum\u0105 gydant I\u0160L ir \u0160N sergan\u010dius pacientus&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":7326,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[27313],"tags":[],"site":[],"post_item_type":[27345],"class_list":["post-7325","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-gydymo-naujienos"],"acf":{"post_sites":false},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/posts\/7325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/comments?post=7325"}],"version-history":[{"count":0,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/posts\/7325\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/media\/7326"}],"wp:attachment":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/media?parent=7325"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/categories?post=7325"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/tags?post=7325"},{"taxonomy":"site","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/site?post=7325"},{"taxonomy":"post_item_type","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/post_item_type?post=7325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}